Assurance in clinical trial design

被引:211
作者
O'Hagan, A
Stevens, JW
Campbell, MJ
机构
[1] Univ Sheffield, Ctr Bayesian Stat Hlth Econ, Sheffield S3 7RH, S Yorkshire, England
[2] AstraZeneca R&D Charnwood, Loughborough, Leics, England
[3] Univ Sheffield, Sch Hlth & Related Res, Sheffield S10 2TN, S Yorkshire, England
关键词
assurance; Bayesian analysis; Bayesian clinical trial simulation; binary data; design of experiments; expected power; power; preposterior analysis; prior distribution; sample size;
D O I
10.1002/pst.175
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Conventional clinical trial design involves considerations of power, and sample size is typically chosen to achieve a desired power conditional on a specified treatment effect. In practice, there is considerable uncertainty about what the true underlying treatment effect may be, and so power does not give a good indication of the probability that the trial will demonstrate a positive outcome. Assurance is the unconditional probability that the trial will yield a 'positive outcome'. A positive outcome usually means a statistically significant result, according to some standard frequentist significance test. The assurance is then the prior expectation of the power, averaged over the prior distribution for the unknown true treatment effect. We argue that assurance is an important measure of the practical utility of a proposed trial, and indeed that it will often be appropriate to choose the size of the sample (and perhaps other aspects of the design) to achieve a desired assurance, rather than to achieve a desired power conditional on an assumed treatment effect. We extend the theory of assurance to two-sided testing and equivalence trials. We also show that assurance is straightforward to compute in some simple problems of normal, binary and gamma distributed data, and that the method is not restricted to simple conjugate prior distributions for parameters. Several illustrations are given. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:187 / 201
页数:15
相关论文
共 28 条
[1]  
[Anonymous], 2002, Statistics at square one
[2]   PROJECTION FROM PREVIOUS STUDIES - A BAYESIAN AND FREQUENTIST COMPROMISE [J].
BROWN, BW ;
HERSON, J ;
ATKINSON, EN ;
ROZELL, ME .
CONTROLLED CLINICAL TRIALS, 1987, 8 (01) :29-44
[3]  
De Santis F, 2004, J ROY STAT SOC C-APP, V53, P427
[4]   Bayesian sample size determination for prevalence and diagnostic test studies in the absence of a gold standard test [J].
Dendukuri, N ;
Rahme, E ;
Bélisle, P ;
Joseph, L .
BIOMETRICS, 2004, 60 (02) :388-397
[5]  
Fleiss J. L., 1981, Statistical Methods for Rates and Proportions, V2nd
[6]   A SIMPLE APPROXIMATION FOR CALCULATING SAMPLE SIZES FOR COMPARING INDEPENDENT PROPORTIONS [J].
FLEISS, JL ;
TYTUN, A ;
URY, HK .
BIOMETRICS, 1980, 36 (02) :343-346
[7]   Statistical methods for eliciting probability distributions [J].
Garthwaite, PH ;
Kadane, JB ;
O'Hagan, A .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2005, 100 (470) :680-700
[8]   AN AVERAGE POWER CRITERION FOR SAMPLE-SIZE ESTIMATION [J].
GILLETT, R .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES D-THE STATISTICIAN, 1994, 43 (03) :389-394
[9]   SAMPLE-SIZE FORMULAS FOR NORMAL THEORY T-TESTS [J].
GUENTHER, WC .
AMERICAN STATISTICIAN, 1981, 35 (04) :243-244
[10]  
*ICH, 1998, HARM TRIP GUID E9 ST